Increasing the participation of African American men in prostate cancer clinical trials through education, awareness, support and collaborations. This portal provides clinical trials background information, details for specific trials, personal stories and other resources to support the Rally.

This information is not intended as medical advice for patients. Patients should consult their medical doctor for advice and recommendations about specific clinical trials.

"We must not be left behind with new prostate cancer treatments." PHEN president and founder Thomas A. Farrington talks about his prostate cancer journey and the importance of African American men participating in clinical trials. Information	Understanding the possible benefits for patients when participating in a clinical trial. Clinical trials offer important and unique benefits to patients. Information
Dr. J. Carter Presents Clinical Trials 101 Dr. Carter's brief video presentations provide basic information for patients to better understand clinical trials. Information	What Are Clinical Trials? Information that all patients need to know when considering enrolling into a clinical trial. Information
CA209-9KD This is a clinical research study for men with metastatic prostate cancer (cancer that has spread) that no longer responds to androgen deprivation therapy treatments that lower testosterone. Information	IPATential150 Clinical Trial This trial is for patients with metastatic castration-resistant Prostate Cancer who are eligible for, but have not yet begun, abiraterone (Zytiga) treatment. Information
ARASENS Clinical Trials Summary For men who have metastatic cancer and who have never been treated with chemotherapy or immunotherapy. Information	Triton 2 Clinical Trial For patients with metastatic castration resistant prostate cancer that is progressing following treatment with Zytiga, Xtandi, and taxane based chemotherapy Information
Triton 3 Clinical Trial For patients where hormone therapy no longer keeps the PSA from increasing (metastatic castration resistant prostate cancer) with evidence of BRCA1, BRCA2, or ATM genetic mutations or alterations Information	ENACT Clinical Trial Summary For patients considering active surveillance or currently undergoing active surveillance. Information
EMBARK Clinical Trial Summary For patients with a rising PSA after being treated with surgery, radiation or both. Information	The TRUMPET Registry For men whose prostate cancer has grown or spread despite use of hormonal treatments to lower their PSA; Known as castration-resistant prostate cancer. Information
Low and Intermediate Risk Prostate Cancer Information	Newly Diagnosed High Risk Information
Treated with Prostatectomy /Radiation Information	Recurrent Disease Information
Castration Resistant non-Metastatic Information	Metastatic Castration Resistant Information
Actively Recruiting Trials by Class of Drug A description of the classes of drugs being studied for prostate cancer treatment with a selective listing of actively recruiting trials by class. Information	A listing of all the prostate cancer clinical trials listed on clinicaltrials.gov that are currently recruiting patients. Information
Strategies For Increasing African American Participation in Clinical Trials at Duke Dr. Steven Patierno, Deputy Director, Duke Cancer Institute at Duke Medical Center presents at PHEN's 2016 Summit. Information	Overcoming Barriers to Clinical Trials Participation Dr. Edith Mitchell, Director, Center to Eliminate Cancer Disparities, Sidney Kimmel Cancer Center at Thomas Jefferson University presents at PHEN's 2016 Summit. Information